home > drugs a-z list > robaxin (methocarbamol) drug center > robaxin (methocarbamol) drug - warnings and precautions

Since methocarbamol may possess a general CNS depressant effect, patients receiving robaxin (methocarbamol) ® or robaxin (methocarbamol) ®-750 should be cautioned about combined effects with alcohol and other CNS depressants.

Safe use of robaxin (methocarbamol) ® and robaxin (methocarbamol) ®-750 has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, robaxin (methocarbamol) ® and

robaxin (methocarbamol) ®-750 should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see PRECAUTIONS, Pregnancy).

Use In Activities Requiring Mental Alertness

Methocarbamol may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle. Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that methocarbamol therapy does not adversely affect their ability to engage in such activities.

Included as part of the PATIENT INFORMATION section.

Carcinogenesis, mutagenesis, impairment of fertility

Long-term studies to evaluate the carcinogenic potential of methocarbamol have not been performed. No studies have been conducted to assess the effect of methocarbamol on mutagenesis or its potential to impair fertility.

Pregnancy

Teratogenic effects - Pregnancy Category C

Animal reproduction studies have not been conducted with methocarbamol. It is also not known whether methocarbamol can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity, robaxin (methocarbamol) ® and robaxin (methocarbamol) ®-750 should be given to a pregnant woman only if clearly needed.

Safe use of robaxin (methocarbamol) ® and robaxin (methocarbamol) ®-750 has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, robaxin (methocarbamol) ® and

robaxin (methocarbamol) ®-750 should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see WARNINGS).

Nursing mothers

Methocarbamol and/or its metabolites are excreted in the milk of dogs; however, it is not known whether methocarbamol or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when robaxin (methocarbamol) ® or robaxin (methocarbamol) ®-750 is administered to a nursing woman.

Pediatric use

Safety and effectiveness of robaxin (methocarbamol) ® and robaxin (methocarbamol) ®-750 in pediatric patients below the age of 16 have not been established.

Last reviewed on RxList: 11/1/2010
This monograph has been modified to include the generic and brand name in many instances.